Changes regarding the Spanish Common Package of Benefits

16

Nov 2022

Earlier this year, the Commission of Benefits, Insurance, and Financing made several agreements in cardiovascular and endocrine fields, which were subsequently approved by the Interterritorial Council of the National Health System (CISNS). On October 28, 2022, several Resolutions of the General Directorate of the Common Package of Benefits of the National Health and Pharmacy System in this regard were published concerning the use of the system for percutaneous repair of the mitral valve with clip, prioritization of patients with type 2 diabetes mellitus for the provision of glucose monitoring systems, the use of glucose monitoring system with sensors (flash type) for type 1 diabetes mellitus in childhood and adolescence.

The following key conclusions were provided in these Resolutions respectively:

  • It was outlined that the system for percutaneous repair of the mitral valve with clip should be kept in the Common Package of Benefits of the National Health System under the same conditions as in the monitoring study protocol. The Resolution outlined the patient criteria that must be met, as well as the information on the minimum requirements the hospitals should meet to be eligible to perform this service. This decision was based on the monitoring study by the Basque Office for Health Technology Assessment (OSTEBA);
  • Prioritization criteria for patients with type 2 diabetes mellitus that undergo intensive insulin therapy and require at least six digital punctures per day for self-monitoring of blood glucose, to whom it is necessary to provide glucose monitoring systems were outlined for the following periods: the second half of 2022 and the first half of 2023 (with the commitment to start in the second half of 2022), the first half of 2023, the second half of 2023, throughout 2024. As an example, for the first period mentioned above, the following patient categories are specifically included: patients with visual impairment, functional limitations, disability, dependence, or cognitive impairment that limits or prevents them from performing digital punctures or recognizing, expressing, or acting in a situation of hypoglycemia; patients with a history of severe hypoglycemia defined as those that require health care or help from a third person for its solution (one episode or more in the last two years); patients under 18 years of age; pregnant women or women in the process of pregnancy planning;
  • Suffering inadvertent hypoglycemia is no longer considered an exclusion criterion for the provision of glucose monitoring systems using sensors (flash type) for type 1 diabetes mellitus in childhood and adolescence. Other inclusion and exclusion criteria for this indication have not changed.

The full details in Spanish can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services “HTA Alerts” and “Reimbursement Alerts” every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

22

Nov 2022

On October 27, 2022, the BfArM (Federal Institute for Drugs and Medical Devices) published the final version of the 2023 OPS procedure coding classification. The OPS, together with the ICD-10-GM (International Statistical Classification of Diseases and Related Health Problems, 10th revision, German Modification), forms the basis for the reimbursement systems in outpatient and inpatient care in Germany.

Read more

10

Nov 2022

The French National Authority for Health released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies in October 2022. Fourteen recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services. Opinions concern cardiovascular, neurovascular, orthopedic, and ENT devices, as well as medical aids.

Read more

04

Nov 2022

On October 19, 2022, it was announced by the Ministry of Health that the 2023 General State Budget in the field of health would comprise €2,746.17 million, which is €199.32 million (7.83%) more than in 2022. The aim is to strengthen the National Health System (SNS) and achieve a more robust, more equitable, and more modern system capable of adapting to the population's health needs.

Read more

12

Oct 2022

In September 2022, the French National Authority for Health (HAS) published four new opinions, which were based on health technology assessment reports. They are related to neuromodulation and cardiovascular areas. The main goal of these HTAs was to support decision-making for the creation of new procedure codes in the Common Classification of Medical Procedures (CCAM) and to update the indications for implantable cardiac defibrillators with endocavitary lead(s) in the Intra-DRG list.

Read more

07

Oct 2022

On September 22, 2022, the Austrian version of the DRG system (LKF) 2023 model with the relevant supplementary documents was published in Austria. The document "Changes and innovations in the 2023 LKF model" summarizes the most significant changes and innovations in the LKF model for inpatient and outpatient care. The newly added procedure codes mainly concern cardiovascular, extracorporeal treatments, and peripheral vascular fields.

Read more